Here are five things to know:
1. Merck attributed the profit to a big jump in U.S. medicine sales, particularly for its blockbuster cancer drug Keytruda. Keytruda boosts a patient’s immune system to fight cancer.
2. The loss in the third quarter of 2017 was a result of several one-time expenses, including a cyberattack in June of that year that shut down production.
3. Overall, Merck reported $10.8 billion in global sales in the third quarter of 2018, up 5 percent from the same period one year prior.
4. During the earnings call, the company said it was initiating a $10 billion share buyback program.
5. “We built on our strong momentum during the quarter and believe that Merck is well-positioned to continue creating sustainable value for shareholders and patients,” said Kenneth C. Frazier, Merck chairman and CEO.
More articles on pharmacy:
Drug take back day is Oct. 27: 5 things to know
Amgen cuts list price of $14K-a-year cholesterol drug nearly 60%
Trump’s plan to lower prescription drug prices: 7 takeaways
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.